Executive Summary
Swissmedic recorded a total of 6,647 illegal drug imports in 2025, processed in collaboration with the Federal Customs and Border Security Office (BAZG). While the number of seized shipments remains stable, significant shifts are evident in product types and countries of origin – particularly increasing supplies from the EU. The findings highlight persistent health risks from untested pharmaceuticals and require enhanced market surveillance.
Persons
- Swissmedic (Swiss pharmaceutical approval and supervisory authority)
- Federal Customs and Border Security Office (BAZG)
Topics
- Illegal drug imports
- Market surveillance
- Public health
- Border controls
- Product safety
Clarus Lead
Switzerland's pharmaceutical authority Swissmedic documented increasing professionalization of the illegal drug trade in 2025. With 6,647 processed cases, overall volume remains stable, yet the structure of the illegal market is fundamentally changing: new product categories, reorganized supply chains, and increased imports from the EU require adjustments to control mechanisms. These shifts underscore that illegal networks actively respond to regulatory measures and optimize their strategies.
Detailed Summary
The 2025 annual statistics of the Federal Customs and Border Security Office document market dynamics that challenge traditional control approaches. Although the absolute number of shipments remains constant, product trends suggest that illegal distributors are deliberately shifting to less regulated or harder-to-trace categories. Increasing supplies from EU countries signal a shift in supply chains within the European economic area – possibly a response to enhanced controls on non-European sources.
The professionalization of intermediaries significantly complicates the identification of illegal imports. Organized networks increasingly use legal trade structures as cover, making it difficult to distinguish between legal and illegal transports. For decision-makers in healthcare and customs authorities, this means that technological and analytical capacities for pattern recognition must be expanded to keep pace with the adaptability of illegal markets.
Key Statements
- 6,647 illegal drug imports processed in 2025; shipment numbers stable in multi-year comparison
- Product trends are shifting: New categories indicate market adaptation
- EU becomes primary source: Increasing supplies from European countries
- Professional structures: Organized intermediaries significantly complicate controls
- Enhanced market surveillance necessary: Education and preventive measures remain central
Critical Questions
Evidence & Data Quality: What methods does Swissmedic use to classify product categories, and how reliable is the assignment to "new trends" with potentially incomplete data collection?
Conflicts of Interest & Incentives: What incentives do EU countries have to tighten their export controls if illegal exports generate economic benefits?
Causality & Alternatives: Are the shifts to EU supplies a result of enhanced non-European controls, or do they stem from other factors such as price changes or regulatory gaps?
Feasibility & Risks: What technical and personnel resources are required to compensate for the documented professionalization of illegal networks through enhanced market surveillance?
Health Impacts: How are the specific health risks of the new product categories assessed, and do they differ in their danger from earlier import patterns?
Coordination & Border Efficiency: How effective is the collaboration between Swissmedic and BAZG in identifying patterns over time, and are there capacity limitations?
Source Directory
Primary Source: Illegal Drug Imports 2025: More Shipments, New Product Trends, and Increasing Supplies from the EU – https://www.news.admin.ch/de/newnsb/s7kG42UWqk_MRUU80wyhm
Verification Status: ✓ February 16, 2026
This text was created with the support of an AI model.
Editorial responsibility: clarus.news | Fact-checking: February 16, 2026